Harrow (NASDAQ: HROW) CSO sells 11,250 shares at $40

Q: What did HROW Chief Scientific Officer Amir Shojaei report in this Form 4?

Shojaei reported exercising 11,250 stock options at $35.96 and immediately selling 11,250 common shares at $40.00 on August 14, 2026 in a broker-assisted same-day sale to cover the exercise price and related costs.

Q: How many Harrow (HROW) shares did Amir Shojaei sell and at what price?

Shojaei sold 11,250 shares of common stock of Harrow at a price of $40.00 per share . The sale was part of a broker-assisted same-day sale to fund the aggregate exercise price and related transaction expenses from the option exercise.

Q: What stock option terms for HROW were disclosed for Amir Shojaei?

Shojaei’s option covered 11,250 shares at an exercise price of $35.96 , was granted on January 6, 2025 , and expires on January 6, 2035 . The option vests 25% after one year, with the remainder vesting quarterly through January 6, 2029.

Q: Did Amir Shojaei retain any Harrow (HROW) shares after the reported transactions?

According to the disclosure, Shojaei did not retain any shares acquired upon exercise. All 11,250 shares obtained from exercising the options were sold in the same-day broker-assisted transaction to fund the exercise price and related costs.

Q: How many Harrow (HROW) stock options remain after Amir Shojaei’s transaction?

Following the reported exercise, Shojaei had 18,750 stock options remaining from this award. These options are scheduled to continue vesting in 12 equal quarterly installments until they are fully vested and exercisable on January 6, 2029 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

HARROW, INC. executive Amir Shojaei, Chief Scientific Officer, exercised 11,250 stock options for common stock at an exercise price of $35.96 per share on August 14, 2026. The resulting 11,250 common shares were then sold at $40.00 per share in a broker-assisted same-day sale to fund the aggregate exercise price and related transaction costs, and Shojaei did not retain any of the shares acquired upon exercise. After the transaction, 18,750 stock options under this award remain outstanding, with the option originally granted on January 6, 2025 and vesting through January 6, 2029.

Insider Trade Summary

Exercise and Sale: 11,250 shares ($45K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Shojaei Amir

Role CHIEF SCIENTIFIC OFFICER

Sold 11,250 shs ($450K)

Approx. gross sale proceeds $450K

Approx. exercise cost $405K

Approx. pre-tax spread $45K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F2, F1}	11,250	$35.96	$405K
Exercise	Common Stock	11,250	$35.96	$405K
Sale	Common Stock ^F1	11,250	$40.00	$450K

Holdings After Transaction: Stock Option (Right to Buy) — 18,750 shares (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

F1. The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise.
F2. The option was granted on January 6, 2025. The shares subject to the option vest according to the following schedule: 25% of the shares vested at the one-year anniversary of the date of grant, and the remaining shares vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029.

Key Figures

Options Exercised: 11,250 shares Exercise Price: $35.96 per share Shares Sold: 11,250 shares +5 more

8 metrics

Options Exercised 11,250 shares Stock options for common stock exercised on August 14, 2026

Exercise Price $35.96 per share Exercise price of stock options exercised on August 14, 2026

Shares Sold 11,250 shares Common stock sold on August 14, 2026 in broker-assisted same-day sale

Sale Price $40.00 per share Price per share for common stock sale on August 14, 2026

Options Remaining 18,750 options Total stock options reported as held after the transaction

Option Grant Date January 6, 2025 Grant date of the stock option exercised

Option Expiration Date January 6, 2035 Expiration date of the stock option award

Full Vesting Date January 6, 2029 Date on which the option becomes fully vested and exercisable

Key Terms

broker-assisted same-day sale, aggregate exercise price, stock option (right to buy), vest over the next three years in 12 equal quarterly installments

4 terms

broker-assisted same-day sale financial

"The sale reported ... was effected as part of a broker-assisted same-day sale"

aggregate exercise price financial

"transaction ... to fund the aggregate exercise price and related transaction costs"

stock option (right to buy) financial

"security_title: Stock Option (Right to Buy)"

vest over the next three years in 12 equal quarterly installments financial

"remaining shares vest over the next three years in 12 equal quarterly installments"

FAQ

What did HROW Chief Scientific Officer Amir Shojaei report in this Form 4?

Shojaei reported exercising 11,250 stock options at $35.96 and immediately selling 11,250 common shares at $40.00 on August 14, 2026 in a broker-assisted same-day sale to cover the exercise price and related costs.

How many Harrow (HROW) shares did Amir Shojaei sell and at what price?

Shojaei sold 11,250 shares of common stock of Harrow at a price of $40.00 per share. The sale was part of a broker-assisted same-day sale to fund the aggregate exercise price and related transaction expenses from the option exercise.

What stock option terms for HROW were disclosed for Amir Shojaei?

Shojaei’s option covered 11,250 shares at an exercise price of $35.96, was granted on January 6, 2025, and expires on January 6, 2035. The option vests 25% after one year, with the remainder vesting quarterly through January 6, 2029.

Did Amir Shojaei retain any Harrow (HROW) shares after the reported transactions?

According to the disclosure, Shojaei did not retain any shares acquired upon exercise. All 11,250 shares obtained from exercising the options were sold in the same-day broker-assisted transaction to fund the exercise price and related costs.

How many Harrow (HROW) stock options remain after Amir Shojaei’s transaction?

Following the reported exercise, Shojaei had 18,750 stock options remaining from this award. These options are scheduled to continue vesting in 12 equal quarterly installments until they are fully vested and exercisable on January 6, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 05:48 PM Accepted by SEC EDGAR 08/17/2026 - 05:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shojaei Amir

(Last)

(First)

(Middle)

C/O HARROW, INC.

1A BURTON HILLS BLVD., SUITE 200

(Street)

NASHVILLE

TENNESSEE

37215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HARROW, INC. [ HROW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/14/2026		M		11,250	A	$35.96	11,250	D
Common Stock⁽¹⁾	08/14/2026		S		11,250	D	$40	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)⁽²⁾	$35.96	08/14/2026		M			11,250	⁽¹⁾	01/06/2035	Common Stock	11,250	$35.96	18,750	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected as part of a broker-assisted same-day sale transaction in connection with the option exercise reported herein to fund the aggregate exercise price and related transaction costs. The Reporting Person did not retain any shares acquired upon exercise.

2. The option was granted on January 6, 2025. The shares subject to the option vest according to the following schedule: 25% of the shares vested at the one-year anniversary of the date of grant, and the remaining shares vest over the next three years in 12 equal quarterly installments until fully vested and exercisable on January 6, 2029.

	/s/ Andrew R. Boll, Attorney-in-Fact for Amir H. Shojaei	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR